Enhanced General Purpose Centrifuge Product Line Increases Capacity and Flexibility
New enhanced general purpose centrifuge product line offers clinical and life science researchers the ability to spin more samples in a single run while maximizing critical lab space.
The Thermo Scientific general purpose centrifuges feature increased capacity and flexibility with rotor innovations including the new Thermo Scientific TX-1000 rotor, which is the only rotor on the market that employs a 4-L capacity in a traditional 3-L footprint. In addition, the new Thermo Scientific MicroClick 30 x 2 rotor offers a 30-place capacity for microtube and nucleic acid spin columns, and is ideal for molecular biology applications. These high-capacity rotors are designed to process more tubes in fewer runs, saving time while reducing energy and wear on the centrifuge.
“Clinical and life science researchers using a general purpose centrifuge are always looking to save time, space and money while increasing productivity,” said Maurizio Merli, global product director, centrifugation, for Thermo Fisher Scientific. “Our latest rotor innovations address researchers’ needs by allowing them to spin more samples in one run for increased production without surrendering space, performance or flexibility.”
The Thermo Scientific general purpose centrifuge line is designed for a wide range of clinical and life science applications, from cell culture to bioproduction to proteomics, food safety, pharmaceutical, stem cell, microbiology and genomics. The general purpose centrifuge floor models conserve valuable bench space with an almost 25% smaller footprint compared to refrigerated benchtop models and a working height of 79 cm, providing true ergonomic design for removing tubes and exchanging rotors.
The new rotor innovations in the general purpose centrifuge line offer a number of features and benefits:
• TX-1000 rotor: • Up to 40 X 50 mL conical tubes, 196 blood tubes or 24 microplates
• Advanced lubricant and corrosion resistant coating
• Dual-purpose large bucket design accepts adapters for tubes or microplates
• MicroClick 30 x 2 rotor: • High 30-place volume for 1.5/2.0 mL microtube and nucleic acid spin columns
• ClickSeal biocontainment lid for quick and easy sample access.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...